These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 32660902)

  • 1. Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab.
    Moore DC; Arnall JR; Thompson DL; Martin AL; Robinson J; Ndiaye A; Paul B; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e777-e781. PubMed ID: 32660902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daratumumab infusion reaction rates pre- and post-addition of montelukast to pre-medications.
    Coffman K; Carstens C; Fajardo S
    J Oncol Pharm Pract; 2023 Mar; 29(2):333-337. PubMed ID: 35018845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective review of accelerated daratumumab administration.
    Patel A; Clark S; Espiritu J; Dechen T; Tran Q
    J Oncol Pharm Pract; 2022 Jun; 28(4):816-821. PubMed ID: 33866892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
    Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
    Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of ninety-minute daratumumab infusion.
    Lombardi J; Boulin M; Devaux M; Cransac A; Pistre P; Pernot C; Payssot A; Lafon I; Caillot D; Gueneau P
    J Oncol Pharm Pract; 2021 Jul; 27(5):1080-1085. PubMed ID: 32865161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications.
    Kotchetkov R; McLean J; Nay D; Gerard L; Hopkins S; Didiodato G
    Int J Cancer; 2020 Oct; 147(7):1979-1986. PubMed ID: 32189328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction.
    Aykaş F; Karakuş V; Sevindik ÖG
    J Oncol Pharm Pract; 2024 Mar; 30(2):397-399. PubMed ID: 37990526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Premedication De-Escalation on Incidence of Infusion-Related Reactions With Daratumumab.
    Vazirnia D; Del Rio Verduzco A; Soefje SA; Sanders KA; Sandahl TB
    JCO Oncol Pract; 2024 Feb; ():OP2300470. PubMed ID: 38408288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience.
    De Novellis D; Fontana R; Palmieri S; Della Pepa R; Di Perna M; Cetani G; Esposito D; Amendola A; Delle Cave G; Serio B; Morini D; Rizzo M; Mettivier L; Trastulli F; Rocco S; Pagano A; Barbato S; Leone A; La Magna M; Bianco R; Rascato G; Carobene A; Cuffa B; Iannalfo M; Giudice V; Svanera G; Annunziata M; Pizzuti M; Frigeri F; Califano C; Ferrara F; Pane F; Selleri C
    Target Oncol; 2023 Nov; 18(6):885-892. PubMed ID: 37747623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting.
    Geirnaert M; Howarth J; Martin K; Ricard C; Streilein S; Wasney D; Dao V; Kotb R; Rimmer E; Minuk L
    J Oncol Pharm Pract; 2021 Jun; 27(4):907-910. PubMed ID: 33108988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma.
    Bonello F; Rocchi S; Barilà G; Sandrone M; Talarico M; Zamagni E; Scaldaferri M; Vedovato S; Bertiond C; Pavan L; Bringhen S; Cattel F; Zambello R; Cavo M; Mina R
    Front Oncol; 2022; 12():851864. PubMed ID: 35359355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma.
    Yin XX; Hu Y; Yang Y; Zhang X; Liu L; Cao X; Chen J; Xia Z; Wang Y
    Cancer Med; 2024 Jun; 13(11):e7347. PubMed ID: 38845476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Novel Potential Therapeutic Utility of Montelukast in Alleviating Autistic Behavior Induced by Early Postnatal Administration of Thimerosal in Mice.
    Abdelzaher LA; Hussein OA; Ashry IEM
    Cell Mol Neurobiol; 2021 Jan; 41(1):129-150. PubMed ID: 32303879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic role of lactobacillus and montelukast in combination with metformin in diabetes mellitus complications through modulation of gut microbiota and suppression of oxidative stress.
    El-Baz AM; Shata A; Hassan HM; El-Sokkary MMA; Khodir AE
    Int Immunopharmacol; 2021 Jul; 96():107757. PubMed ID: 33991997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.
    Nooka AK; Gleason C; Sargeant MO; Walker M; Watson M; Panjic EH; Lonial S
    J Oncol Pract; 2018 Jul; 14(7):414-422. PubMed ID: 29996069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies.
    Olabi B; Worboys S; Garland T; Grindlay DJC; Rogers NK; Harman KE
    Clin Exp Dermatol; 2020 Dec; 45(8):980-985. PubMed ID: 32568435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Montelukast as a Rescue and Premedication for Rituximab Infusion Reactions.
    Amatto L; Yacyshyn E
    J Rheumatol; 2024 Aug; 51(8):837. PubMed ID: 38879194
    [No Abstract]   [Full Text] [Related]  

  • 18. A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.
    Stakiw J; Kodad S; LeBlanc R; Sebag M; Hay AE; Kukreti V; Côté J; Camacho F; Fu M; Gul E; Reece D
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):484-490. PubMed ID: 37127473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and Management of Olaratumab Infusion-Related Reactions.
    Van Tine BA; Govindarajan R; Attia S; Somaiah N; Barker SS; Shahir A; Barrett E; Lee P; Wacheck V; Ramage SC; Tap WD
    J Oncol Pract; 2019 Nov; 15(11):e925-e933. PubMed ID: 31268811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
    Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
    Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.